Compare Flowserve Corporation Common Stock (FLS) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flowserve Corporation Common Stock vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Flowserve Corporation Common Stock trades at $70.6 (market cap $8.96B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Flowserve Corporation Common Stock is far larger — about 5.2× Nuvation Bio Inc. Class A Common Stock's market cap, and Flowserve Corporation Common Stock pays a 1.25% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flowserve Corporation Common Stock for 0 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| FLS | NUVB | |
|---|---|---|
Market Cap | $8.96B | $1.71B |
Volume | 1,946,178 | 5,448,712 |
Sector | Industrials | Health |
52-Week High | $92.04 | $9.54 |
52-Week Low | $49.09 | $3.41 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.55B | $1.30B |
Dividend Yield | 1.25% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Flowserve Corporation Common Stock
Flowserve Corporation is a Texas-based manufacturer of engineered flow-control equipment, producing industrial pumps, mechanical seals, valves, and automation products through its Flowserve Pumps Division and Flow Control Division, serving the oil and gas, chemical, power, and water industries in more than 50 countries.
Read more on FLS →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
